SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron

The emergence of SARS-CoV-2 Omicron and other variants of concern (VOCs) has brought huge challenges to control the COVID-19 pandemic, calling for urgent development of effective vaccines and therapeutic drugs. In this study, we focused on characterizing the impacts of divergent VOCs on the antivira...

Full description

Bibliographic Details
Main Authors: Yuanmei Zhu, Xiaojing Dong, Nian Liu, Tong Wu, Huihui Chong, Xiaobo Lei, Lili Ren, Jianwei Wang, Yuxian He
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Emerging Microbes and Infections
Subjects:
SARS-CoV-2
variants of concern
Omicron
fusion inhibitor
lipopeptide
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2022.2098060

Internet

https://www.tandfonline.com/doi/10.1080/22221751.2022.2098060

Similar Items